

***Fiscal Year 2024 Department of Defense Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Academy of Kidney Cancer Investigators – Leadership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPAKCILA</p>	<p>Academy Director and Deputy Director:</p> <ul style="list-style-type: none"> • Supports established kidney cancer researchers with a record of mentoring junior faculty level kidney cancer scientists and/or clinicians. • Must have kidney cancer research funding (past and/or present); and a record of kidney cancer publications in peer-reviewed journals. • Academy Director - must be an independent and established kidney cancer investigator at or above the level of Associate Professor (or equivalent) as of the full application submission deadline. • Deputy Director - must be an independent kidney cancer researcher at the level of Associate Professor (or equivalent) as of the full application submission deadline and at a different institution from the Director. 	<ul style="list-style-type: none"> • Must have vision and plan(s) of how Leadership team will empower Academy-Early Career Scholars to advance research and promote development as next generation of kidney cancer research leaders. • The Academy Director and Deputy Director (leadership) will lead the existing Academy of Early-Career Scholars and their Designated Mentor(s). The Academy consists of early career scientist/clinicians and their designated mentors. • Academy Director and Deputy Director will execute leadership/support, management plans, network opportunities, communication plans, assessments of research and career progression, and outline division of leadership team responsibilities for the Academy. • Clinical trials are <u>not</u> allowed. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • Maximum funding of \$1,500,000 for direct costs (plus indirect costs). • Maximum period of performance is 5 years. 	<p>Pre-Application (Letter of Intent): August 29, 2024 5:00 p.m. Eastern time</p> <p>Application: September 19, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Academy of Kidney Cancer Investigators – Early-Career Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPAKCIECSA</p>	<p>Investigators within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline. <i>A letter attesting to eligibility required.</i></p>	<ul style="list-style-type: none"> • Supports addition of new Early-Career Scholars (ECS) to the unique, interactive virtual academy, which provides intensive mentoring, national networking, and a peer group for junior faculty. • ECSs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • Requires Designated Mentor who is an independent, established kidney cancer investigator with a record of kidney cancer publications in peer-reviewed journals. • Designated Mentor not required to be at the same institution as the ECS. • <i>Preliminary data are required.</i> • <i>Funding for clinical trials is not allowed.</i> • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): September 24, 2024 5:00 p.m. Eastern time</p> <p>Application: October 15, 2024 11:59 p.m. Eastern time</p>
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPCTA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports hypothesis-based, early-phase clinical trials (e.g., phase 0, phase 1, pilot phase 2) to test interventions that will have a major impact in the field of kidney cancer. • Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types. • Investigational New Drug or Investigational Device Exemption application(s), if applicable, must be submitted to the Food and Drug Administration by the Clinical Trial Award application submission deadline. • Letter of support demonstrating proof of possession of sufficient drug supply to conduct study must be provided (if appropriate). • <i>Clinical trials are expected to be initiated within 12 months of the award date.</i> • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): September 24, 2024 5:00 p.m. Eastern time</p> <p>Application: October 15, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPCA</p>	<p>Investigators at all academic levels</p>	<ul style="list-style-type: none"> • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. • Emphasis on innovation. • Funding for clinical trials is not allowed. • Preliminary data are not allowed and should not be submitted. • Blinded review. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$100,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 1 years. 	<p>Pre-Application (Letter of Intent): August 15, 2024 5:00 p.m. Eastern time</p> <p>Application: September 5, 2024 11:59 p.m. Eastern time</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPIDA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research and have the potential to make an important contribution to kidney cancer. • Preliminary data are required. • Innovation and impact are the most important review criteria. • Funding for clinical trials is not allowed. <p><i>Partnering Principal Investigator (PI) Option:</i></p> <ul style="list-style-type: none"> • Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award. • The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. • Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. <p><i>Partnering PI Option:</i></p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,200,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): September 24, 2024 5:00 p.m. Eastern time</p> <p>Application: October 15, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Postdoctoral and Clinical Fellowship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPPCFA</p>	<p>As of full application submission deadline, investigators:</p> <ul style="list-style-type: none"> • Must possess a doctoral and/or medical degree (or equivalent). • Have 4 years or less of postdoctoral and/or mentored clinical research training experience (excluding family medical leave). <p>All other academic ranks are ineligible.</p>	<ul style="list-style-type: none"> • Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers. • Requires participation of a Designated Mentor who is an experienced kidney cancer researcher. • <i>Submission of a Letter of Intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$195,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 15, 2024 5:00 p.m. Eastern time</p> <p>Application: September 5, 2024 11:59 p.m. Eastern time</p>
<p>Translational Research Partnership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524KCRPTRPA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent). One partner must have experience in kidney cancer or kidney cancer patient care.</p>	<ul style="list-style-type: none"> • Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. • This award supports the development of translational research collaborations between two independent, faculty-level investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. • Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to kidney cancer. • Supports translational correlative studies. • Preliminary data to support the feasibility of the research hypothesis(es) and research approaches are required; however, these data do not necessarily need to be derived from studies of kidney cancer. • <i>Funding for clinical trials is not allowed.</i> • <i>Submission of a Letter of Intent is required. An invitation to submit a full application is not required.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 24, 2024 5:00 p.m. Eastern time</p> <p>Application: October 15, 2024 11:59 p.m. Eastern time</p>